Search results
Results from the WOW.Com Content Network
DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin's lymphoma. [1] It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation .
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via ...
Dihydroxyacetone phosphate (DHAP, also glycerone phosphate in older texts) is the anion with the formula HOCH 2 C(O)CH 2 OPO 3 2-. This anion is involved in many metabolic pathways , including the Calvin cycle in plants and glycolysis .
Induction chemotherapy is the first line treatment of cancer with a chemotherapeutic drug. This type of chemotherapy is used for curative intent. [1] [6]: 55–59 Combined modality chemotherapy is the use of drugs with other cancer treatments, such as surgery, radiation therapy, or hyperthermia therapy.
Alkylglycerone phosphate synthase (EC 2.5.1.26, alkyldihydroxyacetonephosphate synthase, alkyldihydroxyacetone phosphate synthetase, alkyl DHAP synthetase, alkyl-DHAP, dihydroxyacetone-phosphate acyltransferase, DHAP-AT) is an enzyme associated with Type 3 Rhizomelic chondrodysplasia punctata. [1] [2] This enzyme catalyses the following ...
The Cancer Drugs Fund (CDF) was introduced in England in 2011.It was established in order to provide a means by which National Health Service (NHS) patients in England could receive cancer drugs that had been rejected by National Institute for Health and Care Excellence because they were not cost effective.
ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin's lymphoma.In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R.
Accepting the review's recommendations, the government advised that NHS hospitals should phase out the use of the LCP over the next 6–12 months, and that "NHS England should work with clinical commissioning groups (CCGs) to bring about an immediate end to local financial incentives for hospitals to promote a certain type of care for dying ...